KHS Inhibitors
KHS inhibitors, also known as potassium hydrogen sulfide inhibitors, belong to a distinct chemical class characterized by their ability to interfere with the biological processes involving potassium hydrogen sulfide (KHS). These inhibitors play a crucial role in scientific research and the elucidation of various physiological and biochemical pathways. KHS itself is a compound composed of potassium cations (K+) and hydrogen sulfide anions (HS−). It is a physiologically relevant molecule found in living organisms and is associated with a range of biological functions, such as signal transduction, cellular metabolism, and ion homeostasis.
KHS inhibitors are designed to modulate or disrupt the action of KHS within biological systems. They function by either binding to the potassium cations or the hydrogen sulfide anions, preventing their interaction and subsequent physiological effects. These inhibitors have proven invaluable in laboratory settings, enabling researchers to investigate the role of KHS in various cellular processes. By selectively blocking KHS, scientists can gain insights into the underlying mechanisms of diseases, as well as explore the broader implications of KHS in normal cellular function. The development and refinement of KHS inhibitors continue to contribute significantly to our understanding of the intricate biochemical pathways within living organisms, offering potential avenues for further scientific discoveries.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL fusion protein. It blocks ATP binding, inhibiting the phosphorylation of downstream signaling pathways, and is studied in the research of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. It competes with ATP for binding to the EGFR kinase domain, inhibiting autophosphorylation and downstream signaling, commonly used for non-small cell lung cancer research. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor targeting Raf kinase, VEGFR, and PDGFR. It disrupts angiogenesis and tumor growth pathways, and it is used for advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits EGFR signaling by binding to the kinase domain, blocking phosphorylation and downstream signaling. It is prescribed for non-small cell lung cancer research. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-kinase inhibitor targeting VEGFR, PDGFR, c-KIT, and others. It inhibits angiogenesis and cell proliferation, used for renal cell carcinoma and gastrointestinal stromal tumors. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor. It hinders phosphorylation of EGFR and HER2, indicated for HER2-positive breast cancer research. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits multiple kinases, including BCR-ABL and Src family kinases. It blocks tyrosine phosphorylation. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib targets BCR-ABL kinase, preventing downstream signaling in CML. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor affecting VEGFR, PDGFR, and others. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib is a pan-BCR-ABL inhibitor designed for CML with T315I mutation, circumventing resistance to other TKIs by blocking ATP binding to the kinase domain. | ||||||